Plain-English translation of NCT06066333 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This study is testing whether , an immunotherapy medication, works safely when given after radiation therapy in people with advanced adrenocortical cancer (a rare cancer of the adrenal glands). The goal is to see if combining these two treatments can help fight the cancer while keeping side effects manageable. About 12 people will participate.
Adrenocortical cancer is a rare and difficult-to-treat cancer, especially when it has spread to multiple organs. Researchers believe that combining radiation therapy with the medication may help the immune system fight cancer more effectively than either treatment alone.
You likely qualify if…
You likely don't qualify if…
You would first receive radiation therapy targeted at your cancer sites. After that, you would receive injections on a regular schedule. Throughout the study, you'll have regular visits for blood tests, imaging scans, and check-ins to monitor how you're doing and watch for side effects. The research team will also ask to use archived tissue from your original biopsy to study how your cancer responds to the treatment.
AI-generated summary from trial data · Jun 12, 2026 · Not medical advice
United States